Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,360.0
12.1 (0.36%)

 

  • STI Straits Times Index
    3,360.0
    12.1 (0.36%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,668.9
    -3.4 (-0.21%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,619.6
    64.7 (0.23%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,937.6
    -4.6 (-0.16%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,535.2
    -150.7 (-0.69%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,401.9
    -16.4 (-0.25%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,091.9
    9.4 (0.45%)
    Index delayed 20 minutes
  • XAO XAO
    6,735.8
    -10.4 (-0.15%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 743.6M
  • Value: 810.2M
  • Rise: 172
  • Fall: 146
  • Unch: 519

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
SunMoonFood^0.060+0.008
Asian Pay Tv Tr0.184-0.002
Sino Grandness0.047+0.002
G Invacom^0.133+0.005
BHG Retail Reit0.705+0.010
Koh Eco0.050+0.003
ISR Capital^0.003-
Genting Sing0.925+0.005
YZJ Shipbldg SGD1.520+0.030
SingTel3.520+0.020

World Indices

World Indices
Name Last Change
Nasdaq 8,258.2 +14.1
HSI 28,619.6 +64.7
HSCEI 10,865.5 +26.5
Jakarta 6,401.9 -16.4
Nikkei 225 21,535.2 -150.7
SSE Comp 2,937.6 -4.6
Shanghai A 3,076.8 -4.8
Shanghai B 290.7 -1.0
ShenZhen A 1,643.8 -0.6
ShenZhen B 978.3 -1.4
Taiwan W 10,886.0 +9.6
PSE Comp 0.0
KOSPI 2,091.9 +9.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

DPHARMA DUOPHARMA BIOTECH BERHAD
Quotes 15 Minutes Delayed. Updated at 16 Jul 2019 16:51
Last (MYR): 1.380 Change: +0.010 High: 1.390 Remarks: s
Remarks legend:
RemarksDescriptionRemarksDescription
IOrder entry forbiddenAOrder entry authorized
GFrozenSSuspended
RReservedsShort selling available
[x]Exclude dividend[c] Cum dividend
Change (%): +0.73 Low: 1.370
Open 1.370 Yesterday's Close 1.370
Buy Price 1.370 Sell Price 1.380
Buy Volume ('00) 7 Sell Volume ('00) 169
Cumulative Volume ('00) 5,390 Cumulative Value 742,253
Click to show Stock Prices chart

Key Statistics

EPS (MYR) a 0.07198 Trailing EPS (MYR) e 0.07775 NAV (MYR) b 0.7525
PE a 19.172 Trailing PE f 17.750 Price / NAV b 1.8339
Dividend (MYR) d 0.055000 Cash In Hand (MYR) g 0.1118 Issued & Paid-up Shares c 661,881,000
Dividend Yield (%) d 3.986 Price / Cash In Hand g 12.343 Treasury Shares h -
Beta - 75 Daysi 0.280 R-Squared - 75 Days(%)i 0.46 Market Cap (M) 913.396
Beta - 500 Daysi 0.868 R-Squared - 500 Days (%)i 6.98 Enterprise Value (M) 1,085.417
Piotroski F Score 6 Exchange Code 7148 Par Value ( MYR ) 0.50000
52 Weeks Volatility (%) 26.90 6-Month VWAP 1.259 Free Float (%) 42.7
Shariah Compliant Stocks Yes
Sector & Industry Health Technology - Biotechnology
Index Components BM HEALTH CARE
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 13 Jun 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jun 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference DPHARMA Bursa 913.396 19.172 17.750 1.8339 3.986
Industry Biotechnology Bursa 322.893 21.939 20.090 1.6692 3.758
PHARMACEUTICALS Bursa 491.129 16.750 15.998 1.7294 3.295
Index BM HEALTH CARE Bursa 7,387.920 45.325 44.784 2.8660 0.844
Local Peer MGRC Bursa 28.983 - - 1.6777 -
Local Peer MEGASUN Bursa 26.302 25.120 37.735 0.4049 -
Global Peer AMGEN INC NASDAQ 107,421.928 12.797 13.303 9.9171 3.095
Global Peer GILEAD SCIENCES INC NASDAQ 86,555.089 15.867 14.690 3.9431 3.377
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CSL ASX 100,864.210 45.204 41.403 14.6345 1.024
Global Peer CELGENE CORP NASDAQ 64,714.658 15.995 13.638 7.9259 -
Global Peer BIOGEN INC NASDAQ 45,297.283 10.224 9.707 3.2753 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 45,172.061 21.548 20.963 9.5637 -
Global Peer ILLUMINA INC NASDAQ 44,436.630 53.797 52.217 11.1510 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,694.156 13.375 13.468 3.4616 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,590.120 355.545 66.259 2.8424 -
Other Global Peers AGILENT TECHNOLOGIES INC (NYSE), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), EXACT SCIENCES CORP (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), SAREPTA THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), SEATTLE GENETICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), 3SBIO (HKEx), Lonza (SGX), TILRAY INC (NASDAQ), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ACCELERON PHARMA (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), OPKO HEALTH INC (NASDAQ), ALECTOR INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), EPIZYME INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), HAOHAI BIOTEC (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), RETROPHIN INC (NASDAQ), FRONTAGE (HKEx), HOMOLOGY MEDICINES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), DECIPHERA PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), ASCLETIS-B (HKEx), ARVINAS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MACROGENICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), OMEROS CORP (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), PERSONALIS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CYTOKINETICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), CYTOMX THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), CKLIFE SCIENCES (HKEx), MAGENTA THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD (ASX), AKEBIA THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ESSEX BIO-TECH (HKEx), SYNTHORX INC (NASDAQ), NEXT SCIENCE LTD (ASX), CHEMOCENTRYX INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), DERMIRA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), LEE'S PHARM (HKEx), AVROBIO INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEXTCURE INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), RESTORBIO INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), IMMUNOGEN INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), MERUS B V (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), PROQR THERAPEUTICS N V (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), AGENUS INC (NASDAQ), KADMON HLDGS INC (NYSE), SYROS PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), SYNLOGIC INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), TELIX PHARMACEUTIC (ASX), LA JOLLA PHARMACEUTICAL CO (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), KAMADA (NASDAQ), ATHERSYS INC (NASDAQ), GERON CORP (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), CHIASMA INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AFFIMED N V (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), CHIMERIX INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), STANDARD DIVERSIFIED INC (NYSE American), ENZO BIOCHEM INC (NYSE), X4 PHARMACEUTICALS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), XOMA CORP (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ARDELYX INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), IMV INC (NASDAQ), PFENEX INC (NYSE American), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), CUE BIOPHARMA INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), BBI LIFE SCI (HKEx), BIOTIME INC (NYSE American), TOCAGEN INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SESEN BIO INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), HEMISPHERX BIOPHARMA INC (NYSE American), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NANTKWEST INC (NASDAQ), INMUNE BIO INC (NASDAQ), VERASTEM INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), CHAMPIONS ONCOLOGY INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), CATALYST BIOSCIENCES INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TREVENA INC (NASDAQ), UNI-BIO GROUP (HKEx), ITERUM THERAPEUTICS PLC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), EQUILLIUM INC (NASDAQ), SAVARA INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), PORT (SET), VERMILLION INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), INFLARX N V (NASDAQ), CURIS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), ALPINE IMMUNE SCIENCES INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), OTONOMY INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), SURFACE ONCOLOGY INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), IDERA PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), ORGENESIS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ARAVIVE INC (NASDAQ), CEL-SCI CORP (NYSE American), IBIO INC (NYSE American), SUNESIS PHARMACEUTICALS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), IMMUTEP LTD (ASX), REGENT PACIFIC (HKEx), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), CT ENTERPRISE (HKEx), OPIANT PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), IVERIC BIO INC (NASDAQ), ORTHOCELL LIMITED (ASX), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PHYLOGICA LIMITED (ASX), SEELOS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), ZAFGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ZELDA THERAPEUTICS LTD (ASX), CIDARA THERAPEUTICS INC (NASDAQ), BIOTRON (ASX), INVEX THERAPEUTICS LTD NPV (ASX), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), CONTRAFECT CORP (NASDAQ), IMUGENE LIMITED (ASX), BIO-PATH HOLDINGS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), SENESTECH INC (NASDAQ), EXTRAWELL PHAR (HKEx), SOPHIRIS BIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), RHINOMED LIMITED (ASX), AEVI GENOMIC MEDIC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), BIOSINO BIO-TEC (HKEx), ONCOLYTICS BIOTECH INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), ORAGENICS INC (NYSE American), MICROBOT MEDICAL INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), ISORAY INC (NYSE American), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), CELLECTAR BIOSCIENCES INC (NASDAQ), BIOCEPT INC (NASDAQ), HISTOGENICS CORP (NASDAQ), MEMPHASYS LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), PRECIPIO INC (NASDAQ), ADALTA LTD (ASX), FIBROCELL SCIENCE INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOLIGENIX INC (NASDAQ), VICAL INC (NASDAQ), ATYR PHARMA INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), BIONOMICS LTD (ASX), OHR PHARMACEUTICAL INC (NASDAQ), NANOVIRICIDES INC (NYSE American), CO DIAGNOSTICS INC (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), IMMURON LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), NEUBASE THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ADVAXIS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), CELLMID LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), REGENEUS LTD (ASX), TROVAGENE INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), VAXART INC (NASDAQ), BIOXYNE LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), Suntar Eco-City^ (SGX), HOLISTA COLLTECH LIMITED (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), BENITEC BIOPHARMA LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), ANATARA LIFESCIENCES LTD (ASX), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), HAO WEN HLDGS (HKEx), ACTINOGEN MEDICAL LTD (ASX), QT Vascular (SGX), NEURALSTEM INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), OPGEN INC (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), NOVITA HEALTHCARE LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), MEDIBIO LIMITED (ASX), BPH ENERGY LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), ALCHEMIA LIMITED (ASX), SINOVAC BIOTECH (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.010
+0.73 %
10 Days -+0.010
+0.73 %
20 Days 0.040+0.010
+3.65 %
Medium Term Return 3 Months 0.040+0.040
+5.97 %
6 Months 0.040+0.380
+42.00 %
1 Year 0.055+0.130
+14.80 %
Long Term Return 2 Years 0.080+0.450
+56.99 %
3 Years 0.145+0.497
+72.71 %
5 Years 0.425+0.341
+73.72 %
Annualised Return Annualised --
+11.68 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.925 - 1.440 Change From 1 Year Low +0.455 % Change From 1 Year Low (%) +49.19
Change From 1 Year High -0.060 % Change From 1 Year High (%) -4.17
2 Years Range 0.844 - 1.490 Change From 2 Years Low +0.536 % Change From 2 Years Low (%) +63.45
Change From 2 Years High -0.110 % Change From 2 Years High (%) -7.38
5 Years Range 0.814 - 1.490 Change From 5 Years Low +0.566 % Change From 5 Years Low (%) +69.47
Change From 5 Years High -0.110 % Change From 5 Years High (%) -7.38
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CCM Duopharma Biotech Berhad, an investment holding company, engages in the manufacture, distribution, import, and export of pharmaceutical products and medicines in Malaysia. It offers various over the counter products, including analgesic/anti-pyretics, antibacterial mouthwash, childrens vitamins, cough preparations, dermatology products, eye drops, first aid dressings, and health suppliments. The company provides its products in various forms, such as tablets, capsules, syrup, oral antibiotic, creams, haemodialysis solution, sterile irrigation solution, sterile powder injectables, small volume injectables, dental cartridges, and eye drop preparations. It exports its products to various countries, including Vietnam, Ethiopia, Sudan, South East Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, Republic of Yemen, Singapore, and Hong Kong. The company was founded in 1979 and is based in Klang, Malaysia. CCM Duopharma Biotech Berhad is a subsidiary of CCM Marketing Sdn. Bhd.

IPO Performance

Listing Date 18 Jul 2002 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) 7.50 Public Offer Subscription Rate (x) -
IPO Price (MYR) 2.100 First Day Close (MYR) 1.043 First Week Close (MYR) 1.006
Current vs IPO Price (%) -34.29 First Day Gain (%) -50.33 First Week Gain (%) -52.10

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(2.61 MB)
Part 2(2.17 MB)
Annual Report 2018 Apr 2018 Part 1(1.46 MB)
Part 2(0.88 MB)
Part 3(0.27 MB)
Part 4(2.43 MB)
Part 5(1.63 MB)
Annual Report 2016 Dec 2016 Part 1(2.85 MB)
Part 2(0.73 MB)
Annual Report 2015 Dec 2015 Part 1(0.08 MB)
Part 2(2.44 MB)
Part 3(0.02 MB)
Part 4(0.04 MB)
Annual Report 2014 Dec 2014 Part 1(2.20 MB)
Annual Report 2013 Dec 2013 Part 1(1.34 MB)
Annual Report 2012 Dec 2012 Part 1(1.64 MB)
Annual Report 2011 Dec 2011 Part 1(1.12 MB)
Part 2(0.11 MB)
Annual Report 2010 Dec 2010 Part 1(2.37 MB)
Annual Report 2009 Dec 2009 Part 1(2.87 MB)
Part 2(0.15 MB)
Annual Report 2008 Dec 2008 Part 1(0.82 MB)
Annual Report 2007 Dec 2007 Part 1(0.04 MB)
Part 2(2.16 MB)
Annual Report 2006 Dec 2006 Part 1(1.01 MB)
Part 2(0.02 MB)
Annual Report 2005 Dec 2005 Part 1(0.30 MB)
Part 2(0.82 MB)
Annual Report 2004 Dec 2004 Part 1(0.52 MB)
Part 2(1.35 MB)
Annual Report 2003 Dec 2003 Part 1(0.63 MB)
Annual Report 2002 Dec 2002 Part 1(1.12 MB)
Part 2(0.42 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
16 Jul 2019 1.370 1.390 1.370 1.380 539,000 1.3771
15 Jul 2019 1.370 1.390 1.370 1.370 134,200 1.3766
12 Jul 2019 1.430 1.430 1.360 1.370 1,577,900 1.3789
11 Jul 2019 1.370 1.430 1.360 1.400 2,174,400 1.3893
10 Jul 2019 1.370 1.380 1.370 1.370 781,800 1.3701
09 Jul 2019 1.370 1.370 1.370 1.370 375,400 1.3700
08 Jul 2019 1.360 1.370 1.350 1.370 679,800 1.3584
05 Jul 2019 1.370 1.380 1.350 1.370 641,900 1.3661
04 Jul 2019 1.380 1.380 1.370 1.380 216,200 1.3707
03 Jul 2019 1.370 1.380 1.370 1.370 86,600 1.3700
02 Jul 2019 1.370 1.380 1.360 1.370 381,600 1.3696
01 Jul 2019 1.370 1.370 1.360 1.370 948,900 1.3687
28 Jun 2019 1.360 1.370 1.350 1.370 357,400 1.3623
27 Jun 2019 1.350 1.360 1.340 1.350 217,800 1.3536
26 Jun 2019 1.340 1.360 1.340 1.350 230,300 1.3505
25 Jun 2019 1.370 1.380 1.360 1.380 750,000 1.3627
24 Jun 2019 1.360 1.380 1.360 1.370 607,100 1.3680
21 Jun 2019 1.380 1.380 1.340 1.350 990,300 1.3578
20 Jun 2019 1.370 1.380 1.370 1.370 236,700 1.3711
19 Jun 2019 1.370 1.390 1.370 1.380 193,800 1.3788
18 Jun 2019 1.380 1.380 1.360 1.370 162,700 1.3697
17 Jun 2019 1.370 1.370 1.360 1.370 606,000 1.3700
Summary
Current 2 Weeks
(03 Jul 2019 to 16 Jul 2019)
1.370 1.430 1.350 1.380 7,207,200 -
Previous 2 Weeks
(19 Jun 2019 to 02 Jul 2019)
1.370 1.430 1.350 1.370 4,913,900 -
4 Weeks from
(16 May 2019 to 18 Jun 2019)
1.320 1.430 1.320 1.370 11,238,000 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.